AlphaStocks
7.4
Consider Buy

Halozyme Therapeutics, Inc. (HALO)

As of Sep 21, 2026, Halozyme Therapeutics, Inc. (HALO) scores 7.4/10 on AlphaStocks' five-model composite, #8 of 168 Health Care stocks. At $113, HALO trades 42% above its model fair value of $79.

Health Care / Biotechnology

S&P MidCap 400

$112.51

Above average across most dimensions. A solid candidate.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 21, 2026

#8out of 168 in Health Care

Is HALOZYME THERAPEUTICS, INC. a Good Investment in 2026?

HALOZYME THERAPEUTICS, INC. (HALO) scores 7.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates HALOZYME THERAPEUTICS, INC. as Attractive (5/9). However, the Graham model rates it Caution — Significantly above fair value. HALOZYME THERAPEUTICS, INC. currently trades 42% above its estimated fair value of $79. HALOZYME THERAPEUTICS, INC. ranks #8 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E44.0ROE113.4Market Cap14B

Estimated Fair Value

$79.3042% above

Trading above estimated fair value. P/e of 44x implies high growth expectations. eps growth of -25% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 0.9 · Fast Grower

Greenblatt

Neutral

Earnings yield 4.1% · ROC 68%

Frequently Asked Questions

Is HALOZYME THERAPEUTICS, INC. (HALO) a good investment?
As of Sep 21, 2026, Halozyme Therapeutics, Inc. (HALO) scores 7.4/10 on AlphaStocks' five-model composite, #8 of 168 Health Care stocks. At $113, HALO trades 42% above its model fair value of $79. That score is above average across most investment dimensions.
What is HALOZYME THERAPEUTICS, INC.'s Piotroski F-Score?
HALOZYME THERAPEUTICS, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is HALO overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $79, HALO appears overvalued. The stock currently trades 42% above its estimated fair value. Trading above estimated fair value. P/e of 44x implies high growth expectations. eps growth of -25% may not justify the premium.
How does HALO compare to other Health Care stocks?
HALOZYME THERAPEUTICS, INC. ranks #8 out of 168 stocks in the Health Care sector, placing it in the top 5% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about HALO?
AlphaStocks evaluates HALO using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 7.4/10.

Similar Stocks

ABBVINCYHRMY

Compare HALO with

ABBV vs HALOHALO vs INCYHALO vs HRMY

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer